Research programme: Huntington's disease therapeutics - CHDI/Sangamo
Latest Information Update: 28 Jul 2021
At a glance
- Originator CHDI; Sangamo BioSciences
- Developer CHDI; Sangamo Therapeutics
- Class
- Mechanism of Action HD protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Huntington's-disease in USA
- 03 Jul 2019 Research programme is still in preclinical development for Huntington’s disease in USA
- 03 Jul 2019 Pharmacodynamics data from preclinical studies in Huntington's disease released by Sangamo Therapeutics